ArticleJournal of molecular medicine (Berlin, Germany)2009
Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion.
Article in Journal of molecular medicine (Berlin, Germany), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Red deer (Cervus elaphus L.) antler stem cell culture medium inhibits prostate cancer cells.Histochemistry and cell biology · 2025Article
- Identification of CSRP1 as novel biomarker for hormone-sensitive prostate cancer by the combination of clinical and functional research.Cancer cell international · 2025Article
- Emerging Proteins in CRPC: Functional Roles and Clinical Implications.Frontiers in oncology · 2022Review
- Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Review
- Cell-type specific potent Wnt signaling blockade by bispecific antibody.Scientific reports · 2018Article
- Oncolytic virotherapy for urological cancers.Nature reviews. Urology · 2016Review
- [Epigenetic regulation of urological tumors. Importance for prognosis and metastasis].Der Urologe. Ausg. A · 2015Review
- Selection strategies for anticancer antibody discovery: searching off the beaten path.Trends in biotechnology · 2015Review
- In Vitro Selection of Cancer Cell-Specific Molecular Recognition Elements from Amino Acid Libraries.Journal of immunology research · 2015Review
- High-content analysis of antibody phage-display library selection outputs identifies tumor selective macropinocytosis-dependent rapidly internalizing antibodies.Molecular & cellular proteomics : MCP · 2014Article
- Suppression of interactions between prostate tumor cell-surface integrin and endothelial ICAM-1 by simvastatin inhibits micrometastasis.Journal of cellular physiology · 2013Article
- Selection and characterization of cell binding and internalizing phage antibodies.Archives of biochemistry and biophysics · 2012Review
- Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells.Bioorganic & medicinal chemistry letters · 2011Article
- Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Transition from hormone-sensitive to hormone-refractory metastatic tumor types poses a major challenge for prostate cancer treatment. Tumor antigens that are differentially expressed during this transition are likely to play important roles in imparting prostate cancer cells with the ability to grow in a hormone-deprived environment and to metastasize to distal sites such as the bone and thus, are likely targets for therapeutic intervention. To identify those molecules and particularly cell surface antigens that accompany this transition, we studied the changes in cell surface antigenic profiles between a hormone-sensitive prostate cancer line LNCaP and its hormone-refractory derivative C4-2B, using an antibody library-based affinity proteomic approach. We selected a naive phage antibody display library to identify human single-chain antibodies that bind specifically to C4-2B but not LNCaP. Using mass spectrometry, we identified one of the antibody-targeted antigens as the ICAM-1/CD54/human rhinovirus receptor. Recombinant IgG1 derived from this single-chain antibody binds to a neutralizing epitope of ICAM-1 and blocks C4-2B cell invasion through extracellular matrix in vitro. ICAM-1 is thus differentially expressed during the transition of the hormone-sensitive prostate cancer cell line LNCaP to its hormone-refractory derivative C4-2B, plays an important role in imparting the C4-2B line with the ability to invade, and may therefore be a target for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.